XJPX
7782
Market cap20mUSD
Oct 09, Last price
505.00JPY
1D
-0.20%
1Q
10.26%
Jan 2017
-63.49%
IPO
-44.46%
Name
Sincere Co Ltd
Chart & performance
P/E
12.47
P/S
0.44
EPS
40.51
Div yield, %
3.36%
Shrs. gr., 5y
0.70%
Rev. gr., 5y
12.23%
Revenues
7.46b
+14.02%
Net income
264m
-12.40%
CFO
367m
-15.68%
Dividend
Dec 29, 202618 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sincere Co., LTD. manufacture and sells contact lenses in Japan. It operates through three segments: Contact Lens, Consulting, and System business. The company also engages in consulting on medical hair removal clinic management, as well as the design, development, sale, and maintenance of package systems for the reuse industry. In addition, it provides management support for medical institutions, medical related businesses, and elderly facility management. The company was incorporated in 2008 and is headquartered in Tokyo, Japan.
Key people
Ken Nakamura
Executive President, President of Subsidiary, Representative Director · since 2021
Yoshio Arabo
Executive Officer, Director of 1st Sales
Toshiyuki Aso
Executive Officer, Director of Marketing
Shinichi Arai
Executive Officer, Director of Administration, Director · since 2016
Takako Kondo
Executive Officer, Director of Pharmaceutical Affairs
Independent Director · since 2022
Independent Director · since 2022
Hiroshi Ogawa
Independent Director · since 2024
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||